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Abstract
Background: Although patients experience radiation proctitis post radiotherapy no internationally tested
instruments exist to measure these symptoms. This Phase IV study tested the scale structure, reliability and
validity and cross-cultural applicability of the EORTC proctitis module (QLQ-PRT23) in patients who were
receiving pelvic radiotherapy.
Methods: Patients (n = 358) from six countries completed the EORTC QLQ-C30, QLQ-PRT23 and EORTC Quality
of Life Group debriefing questions. Clinicians completed the EORTC Radiation Therapy Oncology Group scale.
Questionnaires were completed at four time-points. The module’s scale structure was examined and validated
using standard psychometric analysis techniques.
Results: Three items were dropped from the module (QLQ-PRT23→ QLQ-PRT20). Factor analysis identified five
factors in the module: bowel control; bloating and gas; emotional function/lifestyle; pain; and leakage. Inter-item
correlations were within r = 0.3–0.7. Test-Retest reliability was high. All multi-item scales discriminated between
patients showing symptoms and those without symptomology. The module discriminated symptoms from the
clinician completed scoring and for age, gender and comorbidities.
Conclusion: The EORTC QLQ-PRT20 is designed to be used in addition to the EORTC QLQ-C30 to measure quality
of life in patients who receive pelvic radiotherapy. The EORTC QLQ-PRT20 is quick to complete, acceptable to
patients, has good content validity and high reliability.
Trial registration: Australian and New Zealand Clinical Trials Registry (ANZCTR) ACTRN12609000972224.
Background
‘Radiation proctitis’ or ‘pelvic radiation disease’ is an un-
pleasant recurrent symptom that occurs following pelvic
radiotherapy. Patients present with: anorectal pain, rectal
bleeding and/or blood clots, bowel urgency, frequent
diarrhoea, profuse mucous discharge, faecal and/or
mucous incontinence [1–4]. Symptoms can have profound
social and psychological consequences for patients and
their families [5, 6].
The reported incidence of radiation proctitis ranges be-
tween 2 and 20% [2, 7]. However, the true incidence is
likely to have been underestimated as clinician evaluation
of symptoms utilise toxicity scales which focus on rectal
bleeding and do not include assessment of urgency of
defaecation and/or mucous/faecal incontinence. The
move to conformal radiation techniques and intensity
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modulated radiotherapy has helped to reduce toxicity [8–
10]. Conversely, there has been a trend towards dose es-
calation studies [11], external beam radiotherapy plus high
dose rate brachytherapy [12] and an increase in the range
of indications for pelvic radiation [13]. Prospective trials
are needed to establish the true incidence of the condition,
the effect it has on patients’ quality of life (QoL) and the
best forms of treatment.
QoL instruments provide a reliable and valid method of
assessing the impact of treatment on patients’ lives and
evaluating topical, medical, nutritional and surgical options
[14]. A recent systematic review provides a summary of the
most frequently used QoL questionnaires for prostate can-
cer [15]. The EORTC Quality of Life Group (QLG) mod-
ules developed for cervical (CX24) and prostate (PR25)
cancer are also useful for identifying disease-specific issues,
but do not adequately address problems associated with ra-
diation proctitis. The one questionnaire directly assessing
QoL in patients with radiation proctitis fails to address all
the proctitis related issues and has not been validated inter-
nationally [5]. The EORTC QLG therefore developed and
tested a module specifically for radiation proctitis that
could be administered with the EORTC QLQ-C30 (EORTC
core questionnaire for quality of life) [16]. We have pub-
lished Phase I-III testing of the EORTC proctitis module in
Australia [17] and Phase III pretesting of the module inter-
nationally [18].
The primary objective of this Phase IV study was to test
the scale structure, reliability, validity and cross-cultural
applicability of the proctitis module in patients who were
receiving pelvic radiotherapy.
Methods
This prospective multi-centre study followed the EORTC
QLG guidelines for module development [19]. QoL data
was collected alongside socio-demographic and clinical
background data (including comorbidities). A trial protocol
was developed and reviewed by the EORTC QLG prior to
commencing the study. Ethics approval was gained from
Curtin University and participating sites. The trial was also
registered on the Australian and New Zealand Clinical
Trials Registry (ANZCTR) ACTRN12609000972224.
Participants
Patients were recruited from Australia, Italy, Norway,
Canada (French speaking), France and Germany. This
enabled testing of the module in English, Norwegian,
Italian, German and French. The module was translated
for each language in collaboration with the translation
team at the EORTC Quality of Life Department [20].
Patients were eligible if they were receiving a radical
course of pelvic irradiation (> 45 Gray) and were able to
converse freely in the language that the questionnaire was
written. Patients were ineligible if they had previously
received radiotherapy or the radiation dose prescribed was
less than 45 Gray.
Data collection
Radiation oncologists identified patients eligible for the
study. Written informed consent was obtained. Partici-
pants were recruited from March 2010 and data collec-
tion ceased May 2014.
Data was collected at the following time-points:
1. At least 2 weeks prior to radiotherapy treatment
(when they saw their radiation oncologist) (T1);
2. During first week of treatment (T2);
3. End of treatment (T3);
4. At the three to 6 months scheduled follow-up
appointment, after treatment completion (T4).
Patients completed the first round questionnaires
when they saw their radiation oncologist prior to com-
mencing treatment. On subsequent occasions the ques-
tionnaires were either provided when they were
attending for treatment or posted to them.
Patients completed a demographics questionnaire, the
EORTC QLQ-C30 [16] and the proctitis module
(QLQ-PRT23). They also responded to these debriefing
questions:
a) How long did it take you to complete the
questionnaire?
b) Did anyone help you to complete the
questionnaire?
c) Were there questions that you found confusing or
difficult to answer?
d) Were there questions that you found upsetting?
The treating radiation oncologists completed the
EORTC Radiation Therapy Oncology Group (RTOG)
classification system at each time-point [21].
Recruitment targets
The primary endpoint was to evaluate the scale structure
of the QLQ-PRT23. Using the EORTC QLG guidelines
for sample size calculation the accepted ‘rule of thumb’
is that 15 responses per item are needed [22]. As the
Phase III module had 21 items, and allowing for a 10%
dropout rate, we needed a sample of 350 participants.
Statistical analysis
The original study design was based on the 2002 EORTC
QLG guidelines for module development [19]. The statis-
tical analysis plan was updated to reflect the 2011 EORTC
QLG guidelines for module development(Version 4) [22].
All analyses were conducted using SPSS version 23 with
alpha levels set to p < .05.
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Scale structure
The initial stage of the development of the EORTC proc-
titis module identified seven areas of interest for provid-
ing QoL information specific to radiation proctitis:
incontinence, pain, bleeding, social function, role and
performance, fatigue and emotional function. Of these,
fatigue was dropped after consultation with health pro-
fessionals and patients (Phase 1b). While the question
items in subsequent versions of the proctitis module
(PRT21, PRT23) were based on the remaining six areas,
this paper presents the first formal analysis of the scale
structure of this module.
Because radiation proctitis occurs as a possible side
effect of pelvic radiotherapy the exploration of the scale
structure of the module was performed on T3 (post
treatment completion) data.
Exploratory Factor Analysis (EFA) was used to investi-
gate the structure of QLQ-PRT23 questions 31–51 [23].
Questions 52–54 were not included in the item and
scale structure review analysis because they were
single-item scales and collected specific clinical informa-
tion relevant to patient comfort and future treatment.
The results of the EFA were refined through consult-
ation with the research team. Multi-trait scaling analysis
was used to test the construct validity (convergent and
discriminant validity) of the proposed multi-item scales.
Within the module, convergent validity was considered
adequate when an item was highly correlated to its own
proposed scale corrected for overlap, operationally defined
as r ≥ 0.4 [23]. Discriminant validity was supported when
an item demonstrated lower correlations with other pro-
posed scales compared to its own proposed scale. Possible
scaling errors were flagged when an item correlated more
highly to some other scale compared to its own proposed
scale [16]. Scaling failures were identified when this differ-
ence was greater than two standard errors [23].
Reliability
The homogeneity, usefulness and level of fit of items
within the proposed scale were examined. The internal
reliability for the scales was assessed using Cronbach’s
alpha coefficient with an r ≥ 0.70 considered adequate27.
Intra-class correlations coefficients (ICC) of the pro-
posed scales between T1 (2 weeks before treatment) and
T2 (first week of treatment) data sets and their test
re-test reliabilities were examined. Significant differences
in patient responses were not expected at these
time-points [24]. ICC’s of > 0.7 were considered accept-
able and ICC’s > 0.9 were excellent [25].
Validity
Convergent validity of the QLQ-PRT20 was examined
via correlations with conceptually similar rating scales
from the QLQ-C30. Based on the item names, previous
literature and team discussion prior to analysis the fol-
lowing scales were expected to correlate highly (r ≥ 0.4)
at T3: QLQ-PRT20 Emotional Function/Lifestyle scale
and the QLQ-C30 Global Health Status and Emotional
and Social scales; QLQ-PRT20 Pain scale and the
QLQ-C30 Pain scale.
Two methods were used to assess discriminant valid-
ity: Known Groups Analysis based on age [26], location/
type of tumour, and presence of co-morbidities [27], and
Responsiveness to Change at T2 (first week of treat-
ment) and T3 (Post treatment).
Results
In total, 358 patients participated: 181 from Australia; 86
from Italy; 47 from Norway; 34 from Canada (French
speaking); four from France; and six from Germany. Pa-
tient demographics and clinical characteristics by coun-
try are summarized in Table 1. Further details about the
treatment patients received for each diagnosis are pro-
vided in Additional file 1 and patient comorbidities are
shown in Additional file 2. The attrition rate was 10%.
Qualitative feedback
Qualitative survey responses were received at each
time-point. At T1 responses were received from 281 par-
ticipants. The response rates for follow-up question-
naires were similar (80%). Table 2 summarises response
patterns for the follow-up questionnaires. Overall, 62%
of participants who completed the qualitative follow up
questions at T1 indicated they completed the question-
naires within 10 min, 23.5% took 11–15 min and 11.4%
took 16–20 min. Similar rates were reported across the
other times points.
Thirteen percent found at least one question confusing
at T1, but most of these were related to bowel issues.
Few issues were reported with the bowel related ques-
tions during or post treatment. Overall, the majority of
participants did not have problems understanding the
questions. Of those respondents who provided written
comments: most provided additional clarifications and/
or elaborated on co-morbidity issues.
Completion of QLQ questionnaires
The numbers of patients returning completed QLQ
questionnaires (QLQ-C30 and QLQ-PRT23) was ap-
proximately 98% at T1. For the QLQ-PRT23 missing
item rates were approximately 1%. Question 51 (Q51)
“How unhappy would you feel if you lived the rest of
your life with your bowel habit as it is now?” recorded
the highest missing data (3.7% at T1). Participants may
not have answered this question at T1 because they had
not commenced radiotherapy. The question with the
highest and most consistent rate of missing entries was
Q53 “Highest number of times you had to open your
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bowels in any 24 hour period” with rates between 3 and
4% across T1-T4.
Cultural applicability
Investigation of possible cultural factors influencing the
completion of the QLQ-PRT23 focused on the four
main language groups rather than patient’s country of
treatment: English, Italian, Norwegian and French (see
Table 1).
Comparing these language groups, 78% of women re-
cruited were from the Italian cohort. The Italian cohort
were 2.8 times less likely (odds ratio) to have a comorbid
Table 1 Patient characteristics at study commencement
Patient characteristics Australia Italy Norway French Speaking Germany Totals
Canada France
Number of patients 181 86 47 34 4 6 358
Mean age in years (SD) 69.2 (9.3) 63.7 (10.5) 68.5 (5.6) 69.5 (6.0) 62.5 (9.3) 69.7 (8.2) 67.7 (9.2)
Range in years 25–95 39–82 55–78 56–80 49–70 55–79 25–95
Male % 96.7 64 97.9 100 50 100 88.9
Patients with one or more existing
co-morbidities
105 32 27 26 3 3 196
Site
Anal Canal 3 3
Bladder 2 2 4
Cervix 18 19
Chordoma 1 1
Endometrium 10 10
Iliac Nodes 1 1
Prostate 162 44 44 28 2 6 286
Rectum 15 8 3 5 1 32
Sigmoid Colon 1 1 2
NB: to gain power the cultural applicably analysis was conducted by language group. To achieve this participants from France and Canada were combined into
the French speaking cohorts and the 6 German participants were excluded due to lack of numbers. Data from the German participants was included in the
broader analysis
Table 2 Response patterns for qualitative follow up questions
Time Valid response N’s to items:
Median (range)
Questions
Time to complete Received Help Confusing questions Upsetting questions
< 10 min 10–15 Min > 15 Min No Yes No Yes** No Yes
T1 261 (254–281) 175 66 40 220 34
(30 = family,
4 health
professionals)
228 34 (Q42 n = 6; Q43
n = 3; Q51 n = 3;
Specific to bowel
questions n = 8; other
questions n = 2 or less)
253 6 (Q51 n = 2,
all others
singletons)
T2 249 (242–265) 174 60 31 220 22(15 explicitly
ref., friends or
family, others no
additional info)
222 25 (Uninformative
affirmatives n = 6; C30
questions n = 4;
questioning bowel
questions n = 3; Q41
n = 3; Q 51 n = 3)
243 2 (Q51)
T3 243 (240–255) 154 79 30 213 26 (13 family,
3 health
professionals,
others no
additional info)
220 25 (Uninformative
affirmatives n = 6; C30
questions n = 5;
questioning urinary
issues n = 2; Q41 n = 2;
Q51 n = 3)
238 5 (Singletons
on Q32, 42,
43 & 51,
uninformative
affirmative
n = 1)
T4 233 (229–245) 150 69 26 214 15 (10 family;
others no
additional info)
225 4 (Q51 n = 2; others
singletons for Q49,
52, 54)
225 4 (Q51 n = 2;
singletons for
Q 49, 50, 52
& 54)
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disorder than members of the other language groups
while the French cohort were 2.95 times more likely;
χ2(3) = 18.73, p < .001. The Italian cohort were also
significantly younger (5 years) than the other language
groups; F(3,348) = 8.03, p < .001.
The response patterns for the T3 QLQ-PRT23 was
found to be similar across the language groups although
the Italian and Norwegian cohorts had higher symptom
reporting on some items compared to the French and
English-speaking cohorts: Specifically, items with higher
symptom reporting for the Norwegian cohort were Q32,
42, 43 and high scores for the Italian cohort were Q40
and 48.
Item and scale structure review
Item and scale structure were assessed using the T3
QLQ-PRT23 responses. The QLQ-PRT23 consisted of 23
items with one optional question. The final three questions
(Q52–54) were not included in the item and scale struc-
ture review as they concerned specific clinical information.
After review, items Q41 (presence of dark blood in
stools), Q45 (Have you had to wear a pad because of
your bowel problems?) and Q47 (Have your daily
activities been limited by your bowel problems?) were
dropped due to low prevalence, poor fit and/or
multicollinearity.
The final module analysed was 20 items with an
optional additional question and will now be identified
as EORTC QLQ-PRT20.
Numerous factor structures were explored starting
with the original six areas of interest which showed
relatively poor fit. A five-factor structure best
accounted for the data and after team discussions the
structure shown in Table 3 was chosen as the most
clinically parsimonious. Five factors descriptors were
assigned: Bowel Control; Bloating and Gas; Emotional
Function/Lifestyle; Pain and Leakage.
Multi-trait scaling analysis supported the EFA with
one exception (Q46), which was moved out of the Bowel
Control scale to the Emotional function/Lifestyle to cor-
rect for an indicated scaling failure. The results of the
final multi-trait scaling analysis are in Table 4.
Reliability
Overall, the reliability of the scales were acceptable with
Cronbach α’s exceeding 0.70 for Bowel Control, Bloating
Table 3 Scale structure for the proposed EORTC QLQ PRT20 module
Scale Question
Bloating and Gas Q31. Have you had a bloated feeling in your abdomen?
Bloating and Gas Q32. Were you troubled by passing wind / gas / flatulence?
Bloating and Gas Q33. Have you had excessive gurgling noise from your abdomen?
Leakage Q34. Have you had any unintentional release (leakage) of wind or mucous?
Leakage Q35. Have you had any unintentional release (leakage) of liquid stools?
Bowel Control Q36. Have you needed to get up at night to open your bowels?
Bloating and Gas Q37. Have you had abdominal pain or cramping not related to a bowel movement?
Pain Q38. Have you had pain or cramping in your rectum (deep inside the back passage)?
Pain Q39. Have you had pain /discomfort around your anal opening (back passage)?
Pain Q40. Have you had bright blood in your stools?
Bowel Control Q42. Have you been unable to wait 15 min to open your bowels?
Bowel Control Q43. Have you had the feeling of being unable to completely empty your bowels?
Bowel Control Q44. Does passing water cause your bowels to act immediately?
Emotional Function/Lifestyle Q46. Have you had difficulty going out of the house, because you needed to be close to a toilet, because
of bowel problems?
Emotional Function/Lifestyle Q48. Did your treatment restrict the types of food you can eat due to your bowel problems?
Emotional Function/Lifestyle Q49. Did you worry about your bowel problem?
Emotional Function/Lifestyle Q50. Did you feel embarrassed by your bowel problem?
Emotional Function/Lifestyle Q51. How unhappy would you feel if you lived the rest of your life with your bowel habit as it is now?
Single Item questions – not included in item scale testing
Diarrhoea Medication (Single item) Q52. Have you needed to take medication to control diarrhoea?
Bowel openings in 24 h (Single item) Q53. What was the highest number of times you had to open your bowels in any 24 h period? Please
indicate number in box
Requesting more assistance
(Single item)
Q54. Would you like more assistance to manage your bowel problem? (optional question)
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and Gas, and Emotional Function/Lifestyle scales
(Table 4) [28]. The remaining scale; Leakage, was
close to this level (0.693).
Test-retest reliability and validity analyses were per-
formed on the linear transforms (outcomes 0–100) for
the proposed scales similar to that outlined in the
EORTC scoring manual [22]. Pre-treatment test–retest
reliability (T1 and T2) results are presented in Table 5.
The ICCs for each of the multi-item scales were rated as
fair (> 0.6) to acceptable (> 0.7).
Convergent validity
The QLQ-PRT20 scales correlated well with the pre-
dicted scales from the QLQ-C30 (Table 6). Notably, the
QLQ-PRT20 Emotional Functioning/Lifestyle scale dem-
onstrated relatively high correlations with all the selected
scales of the QLQ-C30, and the QLQ-C30 Pain Symp-
tom scale showed similarly high correlations with all the
QLQ-PRT20 multi-item scales with the exception of
Leakage.
Discriminant validity
Known-group comparisons The QLQ-PRT20 scales
were assessed on their ability to discriminate patient
groups based on their age, cancer type (prostate, cervix
or rectal), presence of co-morbidities, and RTOG scores
(Table 7). All QLQ-PRT20 scales discriminated between
patients showing acute symptoms of radiation proctitis and
those without symptomology based on the T3 RTOG rat-
ings (RTOG 0–no symptoms vs. RTOG 1 + acute symp-
toms; p ≤ .02, r’s = 0.16–0.37). Scores for Emotional
Function/Lifestyle (p = 0.011, r = 0.17) and Leakage (p =
0.043, r = 0.14) further discriminated between mild or
moderate symptoms. Examining the point estimates
and 95% CI’s of the QLQ-PRT20 scales based on the
absence or presence of RP symptoms (based on the
RTOG scores) suggest that scores above 20 for the
Bowel Control, Bloating and Gas, and Emotional
Function and Lifestyle scales are indicative of signifi-
cant concern (Additional file 3). For the Pain and
Table 4 Item scaling tests: convergent and discriminant validity for the QLQ PRT20 multi-item scales
QLQ PRT20
Scales
N items
in scale
Convergent validity
(range of correlations)
Discriminant validity
(range of correlations)
Scaling
successesa
Scaling
success
rateb
Homogeneity
(average inter-item r)
Inter-item r > 0.3
& < 0.7 (%)
Within scale
Reliability
(Cronbach’s α)
Bowel Control 4 0. 48–0.59 0.31–0.52 16/16 100% 0.431 100% 0.749
Bloating and
Gas
4 0.48–0.66 0.25–0.46 13/16 81% 0.453 100% 0.767
Emotional
Function/
Lifestyle
5 0.56–0.76 0.26–0.56 19/20 95% 0.526 90% 0.843
Pain 3 0.40–0.67 0.17–0.53 11/12 92% 0.476 100% 0.732
Leakage 2 0.53 0.25–0.43 8/8 100% 0.530 100% 0.693
a Number of convergent correlations significantly higher than the discriminant correlations/total number of correlations, b Scaling success rate scaling success as
a percentage
Table 5 Test – retest reliability from Time 1 (2 weeks before treatment) to Time 2 (week of treatment), ICC and Spearman’s Rho;
multi-item scales linear transformed data, single item scales raw data
QLQ-PRT20 Scales [range], n T1 Mean(SD)
[range]
T2 Mean(SD)
[range]
ICC of proposed scale** or kappa T1 –T2 Spearman’s Rho or Phi
Bowel Control [0–100], 329 8.95(15.43)
[0–83]
10.18(15.60)
[0–100]
0.77 0.68*
Bloating and Gas [0–100], 329 6.35(14.19)
[0–73]
7.58(13.83)
[0–75]
0.61 0.67*
Emotional Function/Lifestyle
[0–100], 328
9.55(13.65)
[0–67]
11.56(14.75)
[0–83]
0.74 0.62*
Pain [0–100], 329 5.17(12.32)
[0–89]
5.51(11.56)
[0–78]
0.76 0.64*
Leakage [0–100], 329 4.68(12.77)
[0–100]
5.72(13.14)
[0–100]
0.67 0.48*
Diarrhoea Medicationa [yes/no], 325 Yes = 8 Yes = 13 0.30 k 0.31P*
Bowel openings in 24 ha
[0 +], 316
2.26(2.23)
[0–25]
2.47(1.96)
[1–20]
0.72 0.70*
Requesting more assistancea
[yes/no], 304
Yes = 33 Yes = 29 0.57 k 0.57P*
a Single item scales raw data, k = kappa, p = Phi, * p < .01, ** linear transformed data
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Leakage scales, scores above 15 appear to be of sig-
nificant concern.
Cancer type/location discriminated between acute
and no symptomology for three of the scales; Bloating
and Gas, Emotional Function/Lifestyle and Pain. Emo-
tional Function/Lifestyle was the best discriminating
scale with both cancers of the rectum and cervix
showing significantly higher social/emotional disturb-
ance ratings than the prostate group (p < .001, r =
0.28rectal and r = 0.25cervix). The Bloating and Gas
scale, reported higher ratings for the cervix compared
to the prostate group (p = .004, r = 0.19). The Pain
scale showed a trend for higher rating in cervix group
compared to the prostate group (p = .074, r = 0.13).
Younger (≤=63 years) respondents reported higher
levels of impact/symptoms for both the Emotional
Functioning/Lifestyle and Bloating and Gas scales
when compared to older (> 74 years) respondents (r
= 0.24 and r = 0.22 respectively).
Responsiveness to change The QLQ-PRT20 scales all
demonstrated a strong ability to detect post treatment
change in the patients from T2 (first week of treat-
ment) to T3 (end of treatment): MeanΔ’s 7.5–12, all
p < .001).
Discussion
This study examined the reliability, validity and psy-
chometric properties of the EORTC QLQ-PRT23 in
an international sample of 358 patients receiving pel-
vic radiotherapy. Individual items and the internal
structure of the scale were reviewed. The revised ver-
sion, the QLQ-PRT20 comprises five dimensions:
Bowel Control; Bloating and Gas; Emotional Func-
tion/Lifestyle; Pain; and Leakage. Three additional
items are included to gain specific clinical information
relevant to patient comfort and future treatment.
The proposed scales structure of the PRT20 have
good internal reliability and face validity. Overall, the
internal psychometric properties are strong. Eighty-six
percent of participants completed the questionnaire
within 15 minutes and participants did not find the
questionnaire problematic/distressing.
The QLQ-PRT20 scales correlated well with the
predicted scales from the QLQ-C30, suggesting good
convergent validity. The QLQ-PRT20 Emotional
Function/Lifestyle scale correlated well with all scales
of the QLQ-30 which is appropriate as they are meas-
uring similar things. Furthermore, the QLQ-C30 Pain
Symptom scale and Global Health Status of the
QLQ-C30 showed moderate-high correlations with all
the QLQ-PRT20 multi-item scales apart from the
Table 6 Pearson correlations between selected scales from the QLQ-C30 and the QLQ-PRT20 scales
Comparative scales Bowel Control Bloating and Gas Emotional function/Lifestyle Pain Leakage
Global Health Status/QoL (QLQ-C30) 0.39 0.39 0.51* 0.35 0.28
Emotional Functioning (QLQ-C30) 0.26 0.27 0.42* 0.30 0.27
Social Functioning (QLQ-C30) 0.29 0.34 0.40* 0.29 0.17
Pain (QLQ-C30 Symptom scale) 0.42* 0.42* 0.47* 0.41* 0.25
* Correlations above 0.4, (all correlations were significant at p < .001)
Table 7 Known groups analyses: Median values, test statistics and p values for the known group’s analysis based on the T3 RTOG
physician ratings, cancer type, upper and lower age quartiles and the presence of comorbidities
QLQ PRT20
Proposed Scale
T3 RTOGa: 0 (n = 108) vs.
1 (n = 153) vs. 2–3c
(n = 36)
Cancer Sitea: Prostate (n = 264, male) vs.
Cervix (n = 18, female) vs. Rectum
(n = 28, M/F = 20/8)
Age quartilesb: lower ≤63 years
(n = 88) vs. upper > 74 years
(n = 95)
Presence of comorbiditiesb:
No (n = 162) vs. Yes (n = 196).
Bowel Control 8.3 vs 16.7 vs 25:
H(2) = 19.9, p < .001
– – –
Bloating and Gas 8.3 vs 16.7 vs 33.3:
H(2) = 20.5, p < .001
16.7 vs 33.3 vs 16.7: H(2) = 38.3,
p < .001
25.0 vs 13.9, U = 2252.5,
p = 0.007
–
Emotional
Function/Lifestyle
0.0 vs 20.0 vs 33.3:
H(2) = 51.4, p < .001
6.7 vs 40.0 vs 36.7: H(2) = 12.8,
p = .002
13.3 vs 6.7, U = 2177.5,
p = 0.003
13.3 vs 10.0, U = 11,742.5,
p = .034
Pain 0.0 vs 11.1 vs 16.7:
H(2) = 20.5, p < .001
16.7 vs 33.3 vs 16.7: H(2) = 7.1,
p = .028
– –
Leakage 0.0 vs 0.0 vs 16.7:
H(2) = 18.1, p < .001
– – –
aIndependent samples Kruskal Wallis Test – H(degrees of freedom), b Independent samples Mann-Whitney U test, c T3 RTOG ratings above 2 were collapsed into
the 2–3 group (there were no category 4 ratings)
NB Nonsignificant results not shown
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Leakage scale. The fact that leakage did not correlate
well with any of the QLQ-C30 items may be because
the scales are measuring different lifestyle compo-
nents and leakage is not likely to be a complaint un-
less patients are receiving pelvic treatment. The items
within the leakage scale focus on unintentional release
(leakage) of wind, mucous or liquid stools which are
pertinent to proctitis. The leakage scale was kept sep-
arate to bowel control and bloating and gas because
the questions focus on different symptoms and
psychometric analyses suggested a better fit as an
individual scale. The Emotional and Social Functioning
on the QLQ-C30 also did not correlate well with bowel
control and bloating and gas on the QLQ-PRT20; how-
ever, this is to be expected because the scales are measur-
ing different lifestyle components.
The Emotional Function/Lifestyle scale discrimi-
nated for tumour type/location, age and presence of
comorbidities. The Bloating and Gas scale discrimi-
nated between tumour type/location and age groups.
This suggests that pain and leakage symptoms were
similar regardless of age, tumour location and comor-
bidities, bowel issues did not vary based on age or
comorbidities and bloating and gas symptoms were
the same regardless of comorbidities.
The QLQ-PRT20 discriminated consistently between
patients showing acute symptoms of radiation procti-
tis and those without symptomology based on the
treating physician RTOG ratings. Scores on the
QLQ-PRT20 Emotional Function/Lifestyle and Leak-
age scales further discriminated between those based
on the degree of their symptomology (mild or moder-
ate symptoms). The QLQ-PRT20 is suitable for meas-
uring patient QoL because it provides more detail
than using a clinician completed RTOG score, par-
ticularly when acknowledging weaknesses of clinician
completed scales such as RTOG have been identified
[29]. The QLQ-PRT20 also demonstrated a good abil-
ity to detect change in symptomology over time
showing it to be appropriate for use in monitoring
acute symptoms following pelvic radiotherapy.
Therefore, we contend that the QLQ-PRT20 along-
side the EORTC QLQ-C30 is a suitable patient re-
ported outcome that can be used to complement
physician completed scales such as the RTOG scale.
It provides a detailed picture of actual symptoms
patients are experiencing following pelvic radiotherapy
as well as providing a measure of how well the
patient is coping with symptoms. The QLQ-PRT20 is
different to site-specific modules because it focuses
on quality of life related to side effects rather than
treatment site and is effective in detecting symptoms
specifically related to bowel issues experienced be-
cause of radiotherapy. We recommend that this
module be used in conjunction with the EORTC
QLQ-C30 to monitor patients’ side effects for pelvic
radiotherapy.
A strength of this study is that it followed the
EORTC QLG guidelines for module development for
designing the study [19] and statistical analysis [22].
Limitations include recruitment of a larger proportion
of prostate cancer patients and less female patients.
The intention of the study was to get broad coverage
across a range of representative diagnoses because the
focus was on treatment-related QOL rather than
diagnosis-specific. Although there were differences in
the populations recruited between the countries (e.g.
more females were recruited from Italy and more
prostate cancer patients overall) the response patterns
for the T3 QLQ-PRT23 (i.e., clinically relevant) were
compared graphically and found to be generally simi-
lar overall across the language groups. A further limi-
tation is that this study did not fully reflect the
coverage of countries/languages recommended within
the EORTC QLG guidelines. The module was tested
in four languages with a large proportion of patients
being recruited from Australia (187/358), which may
have caused some biases in relation to language and
culture. This was due to challenges in accessing and
recruiting sites by the study team. Whilst this clearly
limits the conclusions drawn on the cross-cultural ap-
plicability, the study did cover broader regions based
on language (Australia (English); Norway, Canada/
France and Italy) recommended with the exception of
Eastern Europe. However, it could be argued that it is
unlikely that the results would have been very differ-
ent had more international participants been re-
cruited. Testing of the QLQ-BIL21 similarly reported
that they recruited a larger proportion of participants
in one country [30]. Further research is needed to es-
tablish cross-cultural applicability of this module in
different languages. Despite these limitations, we have
shown that this module is relevant to patients in four
countries with different diagnoses who received pelvic
radiotherapy and demonstrated the scale structure,
validity, reliability, and ability of this instrument to
discriminate between symptoms.
Conclusion
The EORTC QLQ-PRT20 alongside the EORTC
QLQ-C30 module is quick and easy to complete, accept-
able to patients, has good content validity and high reli-
ability (including test-retest reliability). Furthermore, we
have shown that it can discriminate symptoms from
clinician completed scoring and for age, gender and co-
morbidities. Further studies are required to determine
the incidence of proctitis for different tumour sites and
treatment regimens.
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